PROMIS NEUROSCIENCES INC. Amortization of Debt Issuance Costs and Discounts
PROMIS NEUROSCIENCES INC. (PMN) reported Amortization of Debt Issuance Costs and Discounts of $241.85 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2024-04-01
- PROMIS NEUROSCIENCES INC. amortization of debt issuance costs and discounts for the quarter ending 2022-12-31 was -$5.19K, a 104.17% decline year-over-year.
- PROMIS NEUROSCIENCES INC. amortization of debt issuance costs and discounts for the quarter ending 2022-09-30 was -$3.01K, a 102.09% decline year-over-year.
- PROMIS NEUROSCIENCES INC. amortization of debt issuance costs and discounts for the quarter ending 2022-06-30 was $119.50K.
- PROMIS NEUROSCIENCES INC. amortization of debt issuance costs and discounts for the quarter ending 2022-03-31 was $130.56K.
- PROMIS NEUROSCIENCES INC. amortization of debt issuance costs and discounts for fiscal 2022 was $241.85K, a 33.92% decline from fiscal 2021.
- PROMIS NEUROSCIENCES INC. amortization of debt issuance costs and discounts for fiscal 2021 was $366.02K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2022-12-31 | -$5.19K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$8.21K derived: sum of 2 quarters · filed 2024-04-01 | $111.29K derived: sum of 3 quarters · filed 2024-04-01 | $241.85K 10-K · filed 2024-04-01 |
| 2022-09-30 | -$3.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $116.48K derived: sum of 2 quarters · filed 2023-11-14 | $247.05K 10-Q · filed 2023-11-14 | $371.51K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $119.50K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $250.06K 10-Q · filed 2023-08-14 | $374.52K derived: sum of 3 quarters · filed 2023-08-14 | $518.67K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $130.56K 10-Q · filed 2023-05-15 | $255.02K derived: sum of 2 quarters · filed 2023-05-15 | $399.18K derived: sum of 3 quarters · filed 2023-05-15 | |
| 2021-12-31 | $124.46K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $268.61K derived: sum of 2 quarters · filed 2023-03-08 | $366.02K 10-K · filed 2023-03-08 | |
| 2021-09-30 | $144.15K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $241.56K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $97.40K 10-Q · filed 2022-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |